Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Newsom Moves California Toward Psychedelic Therapy

Feb 6 • 2 min read

Last fall, California Governor Gavin Newsom expressed readiness to integrate psychedelic drugs into the state’s mental health treatment framework. Following this, Senators Scott Wiener and Assemblymember Marie Waldron have introduced legislation aimed at realizing Newsom’s vision. This bill proposes the legalization of psychedelic therapy for adults over 21, permitting the use of psilocybin mushrooms, MDMA,…

Police Seizures of Psilocybin are Up 369% Since 2017

Feb 6 • 3 min read

As psychedelics have increased in recent years, so have the risks. Data suggests that police seizures of psychedelics, specifically psilocybin (or magic mushrooms), have surged significantly. We take a look at this correlation between excitement and risk below. Introduction to the Rise in Psilocybin Confiscations Recent research has unveiled a significant uptick in law enforcement…

Alto Neurosciences, Inc. Begins Trading at $16 Per Share

Feb 2 • 3 min read

Alto Neuroscience, Inc. (NYSE: ANRO) recently announced the launch of its significantly expanded initial public offering (IPO), offering 8,040,000 shares of common stock at a price of $16.00 per share. This pricing was at the top end of its initial estimate, which ranged from $14 to $16 per share, aiming for an estimated gross revenue…

Numinus Wellness Inc. Raises $6 Million

Feb 2 • 2 min read

Numinus Wellness Inc. (OTCQX: NUMIF) has successfully orchestrated a financing strategy to secure $6 million by entering into a definitive agreement for a bought deal, co-led by Eight Capital and a consortium including Stifel GMP, announced on Thursday. This financial maneuver involves the consortium’s acquisition of 50 million units of Numinus, priced at $0.12 each….

5 Risks While Operating in the Psychedelics Industry in 2024

Jan 26 • 4 min read

This post is brought to you by R&A Psy-Ins, an insurance broker operating at the forefront of the psychedelics industry. Risk #1 General Liability Insurance is a linchpin for psychedelic businesses and the most essential coverage to protect from a variety of claims including personal injury, bodily harm, property damage, and other situations that may…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354